8-K: Neuronetics Appoints Seasoned Financial Executive Steven Pfanstiel as New CFO, Reaffirms 2025 Financial Guidance

Neuronetics, Inc. announced the appointment of Steven Pfanstiel as its new Chief Financial Officer, effective July 15, 2025, while reaffirming its financial guidance for the second quarter and full year 2025.

Summary

• Neuronetics, Inc. appointed Steven Pfanstiel as Executive Vice President, Chief Financial Officer, and Treasurer, effective July 15, 2025.
• Mr. Pfanstiel replaces Steve Furlong, who will transition to Senior Advisor to the CEO until March 31, 2026, to ensure a smooth handover.
• Mr. Pfanstiel brings over two decades of healthcare financial experience, including prior roles as CFO and COO at Marinus Pharmaceuticals, and senior financial leadership at LifeScan and OptiNose, as well as various finance positions at Johnson & Johnson.
• His compensation package includes an initial annual base salary of $480,000, a discretionary annual cash bonus targeted at 50% of his base salary, a $10,000 sign-on bonus, and a grant of 400,000 restricted stock units vesting over three to four years.
• Neuronetics reaffirmed its financial guidance for the second quarter and full year 2025.
• The company expects to achieve positive cash flow in the third quarter of 2025, which is highlighted as a significant operational milestone towards sustained profitability.

Sentiment

Score: 7

Explanation: The announcement of a new, experienced CFO is a positive development, especially with a planned smooth transition. Reaffirming guidance and projecting positive cash flow in the near term are also favorable. The document is a standard 8-K for a management change and financial reaffirmation, not a major breakthrough or setback.

Positives

• Appointment of Steven Pfanstiel, a seasoned financial executive with over two decades of healthcare experience, including medical technology and pharmaceutical sectors.
• Reaffirmation of financial guidance for Q2 and full year 2025, indicating confidence in current projections.
• Anticipated achievement of positive cash flow in Q3 2025, marking a significant operational milestone towards sustained profitability.
• Smooth leadership transition planned with outgoing CFO Steve Furlong remaining as Senior Advisor until March 2026.
• New CFO's experience includes playing a key role in the successful commercial launch of Ztalmy at Marinus Pharmaceuticals.

Risks

• The effect of the Greenbrook transaction on business relationships, operating results, and overall business.
• Ability to execute the business strategy.
• Ability to achieve or sustain profitable operations due to a history of losses.
• Ability to successfully complete announced restructuring plans.
• Reliance on the sale and usage of the NeuroStar Advanced Therapy System to generate revenues.
• The scale and efficacy of the salesforce.
• Ability to retain talent.
• Availability of coverage and reimbursement from third-party payors for treatments using products.
• Physician and patient demand for treatments using products.
• Developments in respect of competing technologies and therapies for the indications that products treat.
• Product defects.
• Revenue concentration among a small number of customers.
• Ability to obtain and maintain intellectual property protection for technology.
• Developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications.
• Developments in regulation in the U.S. and other applicable jurisdictions.
• The terms of the credit facility.
• Ability to successfully roll-out the Better Me Provider Program on the planned timeline.
• Self-sustainability and existing cash balances.
• Ability to achieve cash flow breakeven in the third quarter of 2025.

Future Outlook

Neuronetics reaffirmed its financial guidance for the second quarter and full year 2025, indicating confidence in its current projections. The company anticipates achieving positive cash flow in the third quarter of 2025, which is considered a significant operational milestone on its path to sustained profitability. The strategic vision includes expanding access to mental health treatments and delivering sustainable growth.

Management Comments

• "Steve Furlong has provided outstanding leadership as CFO over the past six years. He has been instrumental in strengthening Neuronetics financial foundation, guiding us through challenging market conditions, and executing the Greenbrook acquisition. His dedication and expertise have been invaluable to our success, and his continued contributions during this transition period will be crucial to maintaining operational excellence." Keith J. Sullivan, President and Chief Executive Officer of Neuronetics.
• "We are thrilled to welcome Steve Pfanstiel to the Neuronetics team as our new CFO. Steve brings exceptional financial leadership along with deep expertise spanning both medical technology and pharmaceutical companies. His proven track record of driving growth and profitability at innovative companies makes him an ideal addition to our leadership team. Steve will be instrumental as we continue executing our strategic vision to expand access to our mental health treatments while delivering sustainable growth." Keith J. Sullivan, President and Chief Executive Officer of Neuronetics.
• "I am excited to join Neuronetics at this pivotal time in the company’s evolution. Neuronetics is clearly at the forefront of caring for patients suffering from mental health disorders. With the combination of its leading NeuroStar TMS technology and the scale of its Greenbrook network of clinics, there is a tremendous opportunity to foster further growth within this significant patient population. I look forward to working with the entire organization to create additional value for patients and shareholders, as we execute on our mission to transform mental healthcare." Steven Pfanstiel, incoming Chief Financial Officer.

Industry Context

The appointment of a new CFO with extensive experience in both medical technology and pharmaceutical sectors aligns with the evolving landscape of mental healthcare, which increasingly integrates advanced medical devices like TMS with pharmaceutical treatments. Neuronetics' focus on expanding access to mental health treatments through its NeuroStar technology and Greenbrook clinic network positions it within a growing segment of the healthcare industry addressing mental health disorders, where demand for non-invasive and effective therapies is rising. The strategic integration of Greenbrook operations further emphasizes a trend towards vertically integrated care delivery models in specialized medical fields.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess Neuronetics' performance against global benchmarks.
• Steven Pfanstiel's previous roles at publicly traded Marinus Pharmaceuticals (specializing in rare diseases and neuroscience), LifeScan Inc. (medical device company focused on diabetes), and OptiNose Inc. (specialty pharmaceutical company) provide a background in relevant healthcare sectors, but no direct performance comparisons are made.
• His experience at Johnson & Johnson, a global healthcare conglomerate, suggests exposure to industry best practices in finance and operations.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO and the reaffirmation of financial guidance, along with the projection of positive cash flow, could instill confidence and potentially positively impact share price. The RSU grant to the new CFO aligns his interests with shareholder value.
• Employees: The planned, smooth transition of the CFO role, with the outgoing CFO remaining as an advisor, suggests stability in leadership.
• Customers: The company's continued focus on expanding access to mental health treatments and delivering sustainable growth implies ongoing commitment to serving patients and providers.
• Creditors: The reaffirmation of financial guidance and the expectation of achieving positive cash flow in Q3 2025 could be viewed favorably by creditors, indicating improved financial health.

Next Steps

• Steven Pfanstiel to begin employment as CFO on July 15, 2025.
• Steve Furlong to remain as Senior Advisor to the CEO until March 31, 2026, to ensure a smooth transition.
• Neuronetics to continue executing its strategic vision to expand access to mental health treatments and deliver sustainable growth.
• Company aims to achieve positive cash flow in the third quarter of 2025.
• Future annual equity grants for Steven Pfanstiel will be evaluated beginning in the 2026 performance year, concluded in January 2027.

Key Dates

Recommendation

Keywords

Neuronetics, CFO appointment, Steven Pfanstiel, Financial guidance, NeuroStar, Medical technology, Mental health, TMS therapy, Greenbrook, Executive change, Financial reporting, Corporate finance, NASDAQ: STIM